產品櫥窗
-
Cyclophosphamide
|
產品型號：101-50-18-0 商品規格： |
 |
Cyclophosphamide is a frequently used chemotherapy, often in combination with other chemotherapy types, for the treatment of breast cancer, malignant lymphomas, multiple myeloma, and neuroblastoma
C7H15Cl2N2O2P
M.W.: 261.09
Cyclophosphamide is a frequently used chemotherapy, often in combination with other chemotherapy types, for the treatment of breast cancer, malignant lymphomas, multiple myeloma, and neuroblastoma.
Cyclophosphamide’s immunomodulatory function was investigated by conditioning macrophages with tumor cell secretome collected from cyclophosphamide treated MM cell lines. CTX-TCS conditioning augmented the migratory capacity of macrophages and increased CD32 and CD64 Fcγ receptor expression on their cell surface. Daratumumab-specific tumor clearance was increased by conditioning macrophages with CTX-TCS in a dose-dependent manner.
In vivo，Cyclophosphamide induces early nonapoptotic death of superficial cells, followed by apoptotic death of deeper layers. H&E staining was performed over several days to determine the global urothelial injury and regeneration pattern after cyclophosphamide injection. Compared with uninjured mice, significant sloughing of urothelial cell layers as well as submucosal hemorrhage and inflammation were observed 1 day after cyclophosphamide. cyclophosphamide induces nonapoptotic death of superficial cells starting at 2 hours, followed by apoptotic loss of intermediate and basal cells starting at 4 hours.
M.W.: 261.09
Cyclophosphamide is a frequently used chemotherapy, often in combination with other chemotherapy types, for the treatment of breast cancer, malignant lymphomas, multiple myeloma, and neuroblastoma.
Cyclophosphamide’s immunomodulatory function was investigated by conditioning macrophages with tumor cell secretome collected from cyclophosphamide treated MM cell lines. CTX-TCS conditioning augmented the migratory capacity of macrophages and increased CD32 and CD64 Fcγ receptor expression on their cell surface. Daratumumab-specific tumor clearance was increased by conditioning macrophages with CTX-TCS in a dose-dependent manner.
In vivo，Cyclophosphamide induces early nonapoptotic death of superficial cells, followed by apoptotic death of deeper layers. H&E staining was performed over several days to determine the global urothelial injury and regeneration pattern after cyclophosphamide injection. Compared with uninjured mice, significant sloughing of urothelial cell layers as well as submucosal hemorrhage and inflammation were observed 1 day after cyclophosphamide. cyclophosphamide induces nonapoptotic death of superficial cells starting at 2 hours, followed by apoptotic loss of intermediate and basal cells starting at 4 hours.
Store at -20°C